Chromogranin a as a marker for bladder cancer
AssigneeCezanne S.A.S.
InventorsBénédicte JARDIN-WATELET, Nicolas BOURGOIN, Tibor SZARVAS
Life of this patent
Estimating the term…
Loading patent…
AssigneeCezanne S.A.S.
InventorsBénédicte JARDIN-WATELET, Nicolas BOURGOIN, Tibor SZARVAS
Estimating the term…
The present invention relates to the use of Chromogranin A (CgA) as a marker (particularly a prognostic marker) for bladder cancer, particularly non-neuroendocrine bladder cancer and preferably urothelial carcinoma. In particular, CgA can be used as a marker in an in vitro assay for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma). The invention further pertains to a method for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma) in a subject, comprising the step of determining the level of CgA and optionally MMP7 in a sample of a bodily fluid of said subject.
An in vitro method for predicting disease-specific survival in a patient diagnosed with non-neuroendocrine bladder cancer comprising:
Dependencies are inferred from the claim text.